Jefferies La santé animale est notre passion. global healthcare conference. London, November 19 Éric Marée

Transcription

1 Jefferies 2014 global healthcare conference London, November 19 Éric Marée La santé animale est notre passion

2 An independant international pharmaceutical group

3 An international presence 736 M turnover + 5.9% vs sales subsidiaries (outside France) 56% companion animals 44% food producing animals Present in more than 100 countries 4,350 collaborators + 5% vs 2012

4 An international presence 736 M North America 14% 33% of the global market Europe 41% 31% of the global market Far East 23% 19% of the global market Latin America 18% 13% of the global market RoW 4% 3% of the global market

5 Independent since more than 40 years Created in 1968 by a French DVM Pierre-Richard Dick Others 50.3% 49.7% Dick family group Stock exchange listed since 1985 today listed NYSE Euronext compartiment A SBF 120 Shareholders The Dick family group holds 65.7% of voting rights

6 Exclusively dedicated to animal health Worldwide ranking Worldwide market: 23 B$ Zoetis Virbac % animal health Ranked 8 th worldwide (M$) Vetnosis Standard Monitor 110 Q4 2013(proforma, excluding non animal health activities)

7 An ingenious range covering the majority of species & pathologies

8 The majority of species & pathologies A complete range: pharmaceutical and biological drugs, nutritionnal and diagnosis product

9 Distribution authorised to the general public in accordance with national regulations (distribution prohibited for France) For an optimal use Products are made for increased convenience and user friendliness higher safety enhanced effectiveness better compliance

10 Pioneer in the companion animal market 19.2 % 16 % 11.3 % 9 % Virbac 5.5% 2.3 % 5.3 % 5.2 % 4.9 % ranked 5 th worldwide 2.1 % (M$) Vetnosis 2013 (sales 2012)

11 Pioneer in the companion animal market A leader position on the following segments vaccines dermatology dental care electronic identification reproduction An innovative petowner offer in markets with high potential internal and external parasiticides petfood

12 Pioneer in the companion animal market MIS Distribution authorised to the general public in accordance with national regulations (distribution prohibited for France)

13 Food producing animals: a dynamic development 20.4 % 18.9 % 11.3 % 7.8 % 6.7 % Virbac 3 % 3.7% 4.2 % 3.6 % Ranked 9 th worldwide 1.5 % (M$) 1 % Vetnosis 2013 (sales 2012)

14 Food producing animals: a dynamic development A buoyant and challenging market regular growth: increased needs for animal proteins throughout the world (especially in emerging countries) economic performance and high product effectiveness are required: regulatory constraints (environmental impact, food safety ) A key positioning on antibiotics and parasiticides An offensive strategy on future segments vaccines (alternatives to antibiotics) aquaculture (the prime source of animal protein worldwide with fishing)

15 Food producing animals: a dynamic development MIS Distribution authorised to the general public in accordance with national regulations (distribution prohibited for France)

16 Sales breakdown by region and business 2013 Europe North America Other developped countries* Emerging countries 41.8% 13.8% 12.7% 31.7% Companion animals 54.9% 29.1% 13.2% 5.6% 6.9% Food producing animals 43% 12.3% 6.4% 24.3% Others 2.1% *Australia, New-Zealand, Japan, Korea

17 A complete range of services MEDICAL EXPERTISE PRACTICE MANAGEMENT CLIENTS RELATIONSHIPS Technical and scientific support (hotline, in practices) Technical training National and international congresses, webcasts (symposiums) e-learning programme Exchange travels for food producing animal veterinarians Management training (marketing, finance, legal ) Merchandising training Audit in practices and coaching Software to help for diagnosis, prescription and dispensing (web tools, ipad, iphone) Tools for quality diagnosis and client satisfaction Tools for petowner loyalty Tools for animal follow-up

18 Continuous technological innovation sensitive to the clients needs

19 A specific innovation model Listening to the client Virbac Innovation Technological advances R&D: a substantial portion of the budget dedicated to development (biologicals and chemical molecules) Formulation: specific skills and know-how to original formulations and techniques Business Development (licensing & acquisitions): companies, products, molecules, formulations

20 A worldwide R&D organisation R&D locations on the 5 continents to fit the specific needs of the main markets USA Mexico Companion animals Ruminants France Thailand Swine Vietnam Aquaculture Aquaculture Chile Santa Elena Australia A global management of projects organized by species

21 A reactive supply chain responding to the highest quality standards

22 A dynamic industrial system A demand-led production Reactive, made-to-measure and flexible (multiple small batches) A special programme to improve industrial competitiveness (Lean manufacturing) An optimised industrial tool An efficient ERP Production units located nears R&D centers

23 The highest international quality standards USA GMP US (FDA & EPA) GMP Europe (EMA) GMP Australia (APVMA) Mexico GMP Mexico (SAGARPA) Chile GMP Europe (EMA) GMP Chili (SAG) France GMP Europe (EMA) GMP US (EPA) Brazil GMP Brésil (MAPA) Uruguay GMP MERCOSUR (DILAVE) RSA GMP RSA (Act 101 & 36) Vietnam GMP Vietnam (WHO) GMP Europe (EMA) Australia GMP Australia (TGA & APVMA) GMP Europe & USA (USDA & EMA) New Zealand GMP New Zealand (ACVM) GMP Australia (APVMA)

24 A close relationship with veterinarians and farmers in every country

25 A sales model based on proximity Client knowledge: search for excellence, needs follow-up (CRM), focus groups, field visit, measure of satisfaction Personalised relationship: availability, advice, warmth, service culture Geographical cover: almost total in each country Partnership B2B win-win: support of the client for the development of its activity (marketing, management, technical training, administration ) and efficient key account management

26 A responsible company focused on the future

27 A responsible company Economic: regular growth, governance transparency, suppliers ethical commitment, local investment Environmental: non-polluting activities, waste and consumption reduction, green IT Social: respect for humankind, encouraging of individual initiative, skills developement, reflection of diversity

28 Growth acceleration in the last 5 years (turnover, M ) % p.a 106,7 +3.9% p.a external % p.a % p.a organic

29 Profits doubled in the last 5 years (M ) Operating profit, recurring Net profit, group share

30 Share price growth: 22.8% p.a. in the last 5 years

31 Thank you for your attention